Loading
Total declarations
Company
▲ Purchases (0 ops.)
▼ Sales (0 ops.)
Latest filing published 23 Feb 2022 for Theravance Biopharma, Inc., €71k. Read the official filing
Insider track record
Disclosed buys
0
Disclosed sells
0
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
Signal history
Ann Brady: trading record in brief
Ann Brady (chief executive) discloses dealings in Theravance Biopharma, Inc. to SEC (Form 4). Between 20 May 2021 and 18 February 2022, the trades on record add up to 4 filings.
Not one of the filings records a straightforward purchase or sale on the market. Compensation-driven entries like these are tracked, but they say little about how insiders judge the share price.
Most recently, on 23 February 2022, the filings show a share grant worth €71k in Theravance Biopharma, Inc. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 4 days. For comparison, the SEC allows two business days to file a Form 4. Source: insider filings from SEC (Form 4). Past trades are no guide to future returns.
Companies and markets linked to Ann Brady
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
Declarations4 total
4 of 4 declarations
